Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CDZ173 dose-finding and placebo-controlled study in APDS/PASLI
NL-OMON47748Phase 3Active, not recruiting
- Sponsor
- Novartis
- Start
- Jun 2016
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of leniolisib in Activated PI3Kδ syndrome (APDS) and immunocompromise (3 arms), sponsored by Novartis. Primary endpoints: Safety and tolerability, Dose-PD and PK/PD relationship and 2 more. Started Jun 2016; status: active, not recruiting.
02
Drugs
leniolisib
03
Conditions
Activated PI3Kδ syndrome (APDS)immunocompromise
Beyond the preview
Go deeper on NL-OMON47748.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON47748.